OliX Pharmaceuticals, Inc (KOSDAQ:226950)
138,000
+4,400 (3.29%)
Nov 20, 2025, 3:30 PM KST
OliX Pharmaceuticals Revenue
OliX Pharmaceuticals had revenue of 6.25B KRW in the quarter ending June 30, 2025, with 35.90% growth. This brings the company's revenue in the last twelve months to 7.54B, down -57.89% year-over-year. In the year 2024, OliX Pharmaceuticals had annual revenue of 5.68B, down -66.73%.
Revenue (ttm)
7.54B
Revenue Growth
-57.89%
P/S Ratio
356.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.69T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.68B | -11.39B | -66.73% |
| Dec 31, 2023 | 17.06B | 7.74B | 83.09% |
| Dec 31, 2022 | 9.32B | 5.65B | 153.66% |
| Dec 31, 2021 | 3.67B | 1.20B | 48.50% |
| Dec 31, 2020 | 2.47B | 1.34B | 118.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |